1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Prowell, TM, Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438–2441.
Google Scholar | Crossref | Medline | ISI3. Masuda, N, Lee, SJ, Ohtani, S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147–2159.
Google Scholar | Crossref | Medline4. Szekely, B, Bossuyt, V, Li, X, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol 2018; 29: 2232–2239.
Google Scholar | Crossref | Medline5. Hutchinson, KE, Yost, SE, Chang, CW, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res 2020; 26: 657–668.
Google Scholar | Crossref | Medline6. Chen, DS, Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541: 321–330.
Google Scholar | Crossref | Medline | ISI7. Schmid, P, Rugo, HS, Adams, S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 44–59.
Google Scholar | Crossref | Medline8. Cortes, J, Cescon, DW, Rugo, HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817–1828.
Google Scholar | Crossref | Medline9. Nanda, R, Liu, MC, Yau, C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020; 6: 676–684.
Google Scholar | Crossref | Medline10. Mittendorf, EA, Zhang, H, Barrios, CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 2020; 396: 1090–1100.
Google Scholar | Medline11. Schmid, P, Cortes, J, Pusztai, L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810–821.
Google Scholar | Crossref | Medline12. Fields, RC, Shimizu, K, Mule, JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482–9487.
Google Scholar | Crossref | Medline13. Qi, CJ, Ning, YL, Han, YS, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother 2012; 61: 1415–1424.
Google Scholar | Crossref | Medline14. Solans, BP, López-Díaz de Cerio, A, Elizalde, A, et al. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: a model-based characterization approach. Br J Clin Pharmacol 2019; 85: 1670–1683.
Google Scholar | Crossref | Medline15. Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164–172.
Google Scholar | Crossref | Medline | ISI16. Park, JH, Jang, M, Tarhan, YE, et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol 2016; 49: 471–478.
Google Scholar | Crossref | Medline17. Finak, G, Bertos, N, Pepin, F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518–527.
Google Scholar | Crossref | Medline | ISI18. Denkert, C, von Minckwitz, G, Darb-Esfahani, S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40–50.
Google Scholar | Crossref | Medline19. Gianni, L, Huang, C-S, Egle, D, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res 2020; 80: GS3-04.
Google Scholar20. Loibl, S, Untch, M, Burchardi, N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30: 1279–1288.
Google Scholar | Crossref | Medline21. Schmid, P, Salgado, R, Park, YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 2020; 31: 569–581.
Google Scholar | Crossref | Medline22. Bracci, L, Schiavoni, G, Sistigu, A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15–25.
Google Scholar | Crossref | Medline | ISI23. Emens, LA, Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015; 3: 436–443.
Google Scholar | Crossref | Medline24. Casares, N, Pequignot, MO, Tesniere, A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691–1701.
Google Scholar | Crossref | Medline | ISI25. Loi, S, Sirtaine, N, Piette, F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860–867.
Google Scholar | Crossref | Medline | ISI26. Mittendorf, EA, Philips, AV, Meric-Bernstam, F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2: 361–370.
Google Scholar | Crossref | Medline | ISI27. Luen, S, Virassamy, B, Savas, P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast 2016; 29: 241–250.
Google Scholar | Crossref | Medline28. Dirix, LY, Takacs, I, Jerusalem, G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167: 671–686.
Google Scholar | Crossref | Medline29. Rugo, HS, Delord, JP, Im, SA, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res 2018; 24: 2804–2811.
Google Scholar | Crossref | Medline30. Sobral-Leite, M, Salomon, I, Opdam, M, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res 2019; 21: 90.
Google Scholar | Crossref | Medline31. Emens, LA, Cruz, C, Eder, JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019; 5: 74–82.
Google Scholar | Crossref | Medline32. Martin-Romano, P, Ammari, S, El-Dakdoukti, Y, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer 2020; 137: 117–126.
Google Scholar | Crossref | Medline33. Hadash-Bengad, R, Hajaj, E, Klein, S, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol 2020; 10: 70.
Google Scholar | Crossref | Medline34. Park, SE, Lee, SH, Ahn, JS, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol 2018; 13: 106–111.
Google Scholar | Crossref | Medline35. Saleh, K, Daste, A, Martin, N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 2019; 121: 123–129.
Google Scholar | Crossref | Medline36. Inoges, S, Tejada, S, de Cerio, AL, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med 2017; 15: 104.
Google Scholar | Crossref | Medline37. Yu, JS, Liu, G, Ying, H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973–4979.
Google Scholar | Crossref | Medline | ISI38. Yamanaka, R, Homma, J, Yajima, N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 4160–4167.
Google Scholar | Crossref | Medline | ISI39. Wheeler, CJ, Black, KL, Liu, G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68: 5955–5964.
Google Scholar | Crossref | Medline40. Fadul, CE, Fisher, JL, Hampton, TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34: 382–389.
Google Scholar | Crossref | Medline | ISI41. De Vleeschouwer, S, Fieuws, S, Rutkowski, S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098–3104.
Google Scholar | Crossref | Medline | ISI42. Joller, N, Kuchroo, VK. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol 2017; 410: 127–156.
Google Scholar | Medline43. Baker, KJ, Houston, A, Brint, E. IL-1 family members in cancer; two sides to every story. Front Immunol 2019; 10: 1197.
Google Scholar | Crossref44. Kumari, N, Dwarakanath, BS, Das, A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016; 37: 11553–11572.
Google Scholar | Crossref | Medline45. Dethlefsen, C, Hojfeldt, G, Hojman, P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013; 138: 657–664.
Google Scholar | Crossref | Medline46. Tumeh, PC, Harview, CL, Yearley, JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–571.
Google Scholar | Crossref | Medline | ISI